Accenture R&D remained flat by 0.0% to $204.33M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 29.0%, from $287.61M to $204.33M. Over 4 years (FY 2021 to FY 2025), R&D shows a downward trend with a -7.5% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ4 2025Oct 10, 2025
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.12B | $1.12B | $1.30B | $1.15B | $817.30M |
| YoY Change | — | +0.4% | +15.6% | -11.4% | -29.0% |
Range$817.30M – $1.30B
CAGR-7.5%
Avg YoY Growth-6.1%
Median YoY Growth-5.5%
Current Streak2 years decline
R&D at Other Companies
Frequently Asked Questions
- What is Accenture's r&d?
- Accenture (ACN) reported r&d of $204.33M in Q2 2025.
- How has Accenture's r&d changed year-over-year?
- Accenture's r&d decreased by 29.0% year-over-year, from $287.61M to $204.33M.
- What is the long-term trend for Accenture's r&d?
- Over 4 years (2021 to 2025), Accenture's r&d has grown at a -7.5% compound annual growth rate (CAGR), from $1.12B to $817.30M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.